Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.83
PDLI's Cash-to-Debt is ranked lower than
74% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. PDLI: 1.83 )
Ranked among companies with meaningful Cash-to-Debt only.
PDLI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.79 Max: No Debt
Current: 1.83
Equity-to-Asset 0.63
PDLI's Equity-to-Asset is ranked lower than
57% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PDLI: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
PDLI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.93  Med: 0.61 Max: 0.98
Current: 0.63
-1.93
0.98
Debt-to-Equity 0.29
PDLI's Debt-to-Equity is ranked lower than
54% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. PDLI: 0.29 )
Ranked among companies with meaningful Debt-to-Equity only.
PDLI' s Debt-to-Equity Range Over the Past 10 Years
Min: -250.06  Med: 0.3 Max: 18.48
Current: 0.29
-250.06
18.48
Interest Coverage 8.12
PDLI's Interest Coverage is ranked lower than
95% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 8.12 )
Ranked among companies with meaningful Interest Coverage only.
PDLI' s Interest Coverage Range Over the Past 10 Years
Min: 4.85  Med: 14 Max: 20.34
Current: 8.12
4.85
20.34
Piotroski F-Score: 4
Altman Z-Score: 2.52
Beneish M-Score: 7.20
WACC vs ROIC
4.46%
11.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 50.51
PDLI's Operating Margin % is ranked higher than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. PDLI: 50.51 )
Ranked among companies with meaningful Operating Margin % only.
PDLI' s Operating Margin % Range Over the Past 10 Years
Min: 50.51  Med: 93.26 Max: 94.93
Current: 50.51
50.51
94.93
Net Margin % 23.03
PDLI's Net Margin % is ranked higher than
79% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. PDLI: 23.03 )
Ranked among companies with meaningful Net Margin % only.
PDLI' s Net Margin % Range Over the Past 10 Years
Min: -9.36  Med: 55.26 Max: 59.61
Current: 23.03
-9.36
59.61
ROE % 9.33
PDLI's ROE % is ranked higher than
78% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. PDLI: 9.33 )
Ranked among companies with meaningful ROE % only.
PDLI' s ROE % Range Over the Past 10 Years
Min: -4.32  Med: 72.89 Max: 1166.18
Current: 9.33
-4.32
1166.18
ROA % 5.92
PDLI's ROA % is ranked higher than
79% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. PDLI: 5.92 )
Ranked among companies with meaningful ROA % only.
PDLI' s ROA % Range Over the Past 10 Years
Min: -1.8  Med: 38.25 Max: 77.05
Current: 5.92
-1.8
77.05
ROC (Joel Greenblatt) % 307.63
PDLI's ROC (Joel Greenblatt) % is ranked higher than
94% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. PDLI: 307.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PDLI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 50.13  Med: 2574.8 Max: 673588.24
Current: 307.63
50.13
673588.24
3-Year Revenue Growth Rate -19.60
PDLI's 3-Year Revenue Growth Rate is ranked lower than
74% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. PDLI: -19.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PDLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -19.6  Med: 14.4 Max: 65.5
Current: -19.6
-19.6
65.5
3-Year EBITDA Growth Rate -31.80
PDLI's 3-Year EBITDA Growth Rate is ranked lower than
84% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. PDLI: -31.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PDLI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 14.4 Max: 433.7
Current: -31.8
0
433.7
3-Year EPS without NRI Growth Rate -38.30
PDLI's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. PDLI: -38.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PDLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.3 Max: 798.3
Current: -38.3
0
798.3
GuruFocus has detected 5 Warning Signs with PDL BioPharma Inc $PDLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PDLI's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PDLI Guru Trades in Q3 2016

Paul Tudor Jones 90,300 sh (New)
Jim Simons 13,472,854 sh (+7.22%)
Barrow, Hanley, Mewhinney & Strauss 299,285 sh (+0.71%)
First Eagle Investment 2,800 sh (unchged)
Jeremy Grantham 2,295,234 sh (-19.55%)
Joel Greenblatt 1,266,121 sh (-44.80%)
» More
Q4 2016

PDLI Guru Trades in Q4 2016

Paul Tudor Jones 292,400 sh (+223.81%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 297,626 sh (-0.55%)
Jim Simons 12,875,700 sh (-4.43%)
Jeremy Grantham 1,070,509 sh (-53.36%)
Joel Greenblatt 29,531 sh (-97.67%)
» More
Q1 2017

PDLI Guru Trades in Q1 2017

Charles Brandes 58,578 sh (New)
First Eagle Investment 2,800 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons 12,036,754 sh (-6.52%)
Paul Tudor Jones 213,284 sh (-27.06%)
Barrow, Hanley, Mewhinney & Strauss 25,387 sh (-91.47%)
Jeremy Grantham 63,997 sh (-94.02%)
» More
Q2 2017

PDLI Guru Trades in Q2 2017

Charles Brandes 1,107,310 sh (+1790.32%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 25,387 sh (unchged)
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Jim Simons 10,704,400 sh (-11.07%)
» More
» Details

Insider Trades

Latest Guru Trades with PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2017-06-30 Add 1790.32%0.05%$2.02 - $2.59 $ 3.3144%1,107,310
Charles Brandes 2017-03-31 New Buy$1.98 - $2.36 $ 3.3150%58,578
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -91.47%$1.98 - $2.36 $ 3.3150%25,387
Joel Greenblatt 2017-03-31 Sold Out $1.98 - $2.36 $ 3.3150%0
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Reduce -0.55%$1.98 - $3.72 $ 3.3119%297,626
Joel Greenblatt 2016-12-31 Reduce -97.67%0.06%$1.98 - $3.72 $ 3.3119%29,531
Joel Greenblatt 2016-09-30 Reduce -44.80%0.04%$2.72 - $3.57 $ 3.314%1,266,121
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 Add 0.71%$2.72 - $3.57 $ 3.314%299,285
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:ACHN, NAS:JNCE, NAS:IOVA, NAS:ASMB, NAS:NK, NAS:ATRA, NAS:CALA, NAS:SNNA, NAS:INO, NAS:TYME, NAS:PGNX, NAS:CARA, NAS:VYGR, LSE:PRTC, NAS:ANIP, NAS:SYRS, NAS:AVEO, NAS:MCRB, NAS:BCRX, NAS:AGEN » details
Traded in other countries:PDL.Germany,
Headquarter Location:USA
PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent.

PDL discovers and develops humanized monoclonal antibodies and receives royalties from nine marketed products licensed under PDL patents. The ESP Pharma acquisition brought marketed products to PDL in 2005, but because of a lack of strategic fit, PDL sold its commercial assets in early 2008. After paying a special dividend to shareholders, PDL has spun off its drug-discovery and -development business and plans to continue distributing royalty-based income to shareholders.

Ratios

vs
industry
vs
history
PE Ratio 7.37
PDLI's PE Ratio is ranked higher than
57% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. PDLI: 7.37 )
Ranked among companies with meaningful PE Ratio only.
PDLI' s PE Ratio Range Over the Past 10 Years
Min: 1.46  Med: 5.33 Max: 26.56
Current: 7.37
1.46
26.56
Forward PE Ratio 23.47
PDLI's Forward PE Ratio is ranked higher than
92% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. PDLI: 23.47 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 7.37
PDLI's PE Ratio without NRI is ranked higher than
58% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. PDLI: 7.37 )
Ranked among companies with meaningful PE Ratio without NRI only.
PDLI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.46  Med: 5.17 Max: 34.42
Current: 7.37
1.46
34.42
Price-to-Owner-Earnings 4.21
PDLI's Price-to-Owner-Earnings is ranked higher than
81% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. PDLI: 4.21 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PDLI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.33  Med: 6.06 Max: 89.35
Current: 4.21
1.33
89.35
PB Ratio 0.64
PDLI's PB Ratio is ranked higher than
98% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. PDLI: 0.64 )
Ranked among companies with meaningful PB Ratio only.
PDLI' s PB Ratio Range Over the Past 10 Years
Min: 0.43  Med: 2.68 Max: 38.99
Current: 0.64
0.43
38.99
PS Ratio 1.69
PDLI's PS Ratio is ranked higher than
86% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. PDLI: 1.69 )
Ranked among companies with meaningful PS Ratio only.
PDLI' s PS Ratio Range Over the Past 10 Years
Min: 0.82  Med: 2.96 Max: 15.85
Current: 1.69
0.82
15.85
Price-to-Free-Cash-Flow 7.95
PDLI's Price-to-Free-Cash-Flow is ranked higher than
87% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. PDLI: 7.95 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PDLI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.3 Max: 390.6
Current: 7.95
1.51
390.6
Price-to-Operating-Cash-Flow 7.87
PDLI's Price-to-Operating-Cash-Flow is ranked higher than
87% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. PDLI: 7.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PDLI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.74 Max: 55.87
Current: 7.87
1.51
55.87
EV-to-EBIT 1.94
PDLI's EV-to-EBIT is ranked higher than
85% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. PDLI: 1.94 )
Ranked among companies with meaningful EV-to-EBIT only.
PDLI' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.8  Med: 3.7 Max: 37.2
Current: 1.94
0.8
37.2
EV-to-EBITDA 1.67
PDLI's EV-to-EBITDA is ranked higher than
86% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. PDLI: 1.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
PDLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.8  Med: 3.5 Max: 15.6
Current: 1.67
0.8
15.6
EV-to-Revenue 1.00
PDLI's EV-to-Revenue is ranked higher than
95% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. PDLI: 1.00 )
Ranked among companies with meaningful EV-to-Revenue only.
PDLI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 3.5 Max: 16.1
Current: 1
0.5
16.1
Shiller PE Ratio 2.93
PDLI's Shiller PE Ratio is ranked higher than
96% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. PDLI: 2.93 )
Ranked among companies with meaningful Shiller PE Ratio only.
PDLI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 1.78  Med: 8.51 Max: 209.25
Current: 2.93
1.78
209.25
Current Ratio 1.94
PDLI's Current Ratio is ranked lower than
75% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. PDLI: 1.94 )
Ranked among companies with meaningful Current Ratio only.
PDLI' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 9.88 Max: 76.07
Current: 1.94
0.26
76.07
Quick Ratio 1.90
PDLI's Quick Ratio is ranked lower than
71% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. PDLI: 1.90 )
Ranked among companies with meaningful Quick Ratio only.
PDLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 9.88 Max: 76.07
Current: 1.9
0.26
76.07
Days Inventory 201.02
PDLI's Days Inventory is ranked lower than
77% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. PDLI: 201.02 )
Ranked among companies with meaningful Days Inventory only.
PDLI' s Days Inventory Range Over the Past 10 Years
Min: 129.48  Med: 129.48 Max: 201.02
Current: 201.02
129.48
201.02
Days Sales Outstanding 24.54
PDLI's Days Sales Outstanding is ranked lower than
92% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. PDLI: 24.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
PDLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.19  Med: 0.9 Max: 226.05
Current: 24.54
0.19
226.05
Days Payable 536.37
PDLI's Days Payable is ranked lower than
91% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. PDLI: 536.37 )
Ranked among companies with meaningful Days Payable only.
PDLI' s Days Payable Range Over the Past 10 Years
Min: 536.37  Med: 629.97 Max: 629.97
Current: 536.37
536.37
629.97

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -45.00
PDLI's 3-Year Dividend Growth Rate is ranked lower than
86% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. PDLI: -45.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PDLI' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -45
Current: -45
5-Year Yield-on-Cost % 0.58
PDLI's 5-Year Yield-on-Cost % is ranked lower than
82% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. PDLI: 0.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PDLI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.54  Med: 2.19 Max: 5.71
Current: 0.58
0.54
5.71
3-Year Average Share Buyback Ratio -5.80
PDLI's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. PDLI: -5.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PDLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9  Med: -5.65 Max: -0.1
Current: -5.8
-7.9
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 9.46
PDLI's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. PDLI: 9.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PDLI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.1  Med: 5.29 Max: 71.33
Current: 9.46
1.1
71.33
Price-to-Tangible-Book 2.06
PDLI's Price-to-Tangible-Book is ranked higher than
85% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. PDLI: 2.06 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PDLI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.86  Med: 2.87 Max: 47.78
Current: 2.06
0.86
47.78
Price-to-Intrinsic-Value-Projected-FCF 0.19
PDLI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. PDLI: 0.19 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PDLI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.13  Med: 3.05 Max: 90.82
Current: 0.19
0.13
90.82
Price-to-Median-PS-Value 0.58
PDLI's Price-to-Median-PS-Value is ranked higher than
68% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. PDLI: 0.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PDLI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 3.77 Max: 31.27
Current: 0.58
0.34
31.27
Price-to-Graham-Number 0.82
PDLI's Price-to-Graham-Number is ranked higher than
76% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. PDLI: 0.82 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PDLI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.34  Med: 2.13 Max: 14.85
Current: 0.82
0.34
14.85
Earnings Yield (Greenblatt) % 51.60
PDLI's Earnings Yield (Greenblatt) % is ranked higher than
96% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. PDLI: 51.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PDLI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.7  Med: 27.25 Max: 119.5
Current: 51.6
2.7
119.5
Forward Rate of Return (Yacktman) % 28.68
PDLI's Forward Rate of Return (Yacktman) % is ranked higher than
91% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. PDLI: 28.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PDLI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7  Med: 7.45 Max: 73
Current: 28.68
-8.7
73

More Statistics

Revenue (TTM) (Mil) $309.41
EPS (TTM) $ 0.45
Beta0.37
Short Percentage of Float11.47%
52-Week Range $1.93 - 3.77
Shares Outstanding (Mil)154.08

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 264 122 210
EPS ($) 0.59 0.14 0.29
EPS without NRI ($) 0.59 0.14 0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PDLI

Headlines

Articles On GuruFocus.com
PDL BioPharma Appoints Dominique Monnet as President Sep 11 2017 
PDL BioPharma to Present at Two Upcoming Investor Conferences Sep 06 2017 
PDL BioPharma to Announce Second Quarter 2017 Financial Results on August 3, 2017 Jul 31 2017 
Noden Pharma Notified of ANDA Filing for Tekturna® Jun 05 2017 
PDL BioPharma to Present at the Jefferies 2017 Healthcare Conference Jun 01 2017 
LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR May 11 2017 
PDL BioPharma Announces First Quarter 2017 Financial Results May 03 2017 
PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017 Apr 26 2017 
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck Apr 24 2017 
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017 Apr 06 2017 

More From Other Websites
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status Sep 20 2017
Should Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock? Sep 20 2017
Pluristem's Ischemia Candidate Gets Fast Track Designation Sep 19 2017
PDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference Sep 19 2017
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio Sep 13 2017
PDL BioPharma Appoints Dominique Monnet as President Sep 11 2017
PDL BioPharma to Present at Two Upcoming Investor Conferences Sep 06 2017
Why PDL BioPharma (PDLI) Could Be Positioned for a Surge Aug 28 2017
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix... Aug 25 2017
Top Ranked Momentum Stocks to Buy for August 24th Aug 24 2017
5 Bargain Breakout Stocks Offering Stunning Returns Aug 24 2017
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock Aug 18 2017
Edited Transcript of PDLI earnings conference call or presentation 3-Aug-17 8:30pm GMT Aug 17 2017
ETFs with exposure to PDL BioPharma, Inc. : August 14, 2017 Aug 14 2017
PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y Aug 07 2017
Here's Why PDL BioPharma Inc. Is Soaring Today Aug 04 2017
PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : August 4, 2017 Aug 03 2017
PDL BioPharma Announces Second Quarter 2017 Financial Results Aug 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}